Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor

被引:45
作者
Errico, M
Riccioni, T
Iyer, S
Pisano, C
Acharya, KR
Persico, MG
De Falco, S
机构
[1] CNR, Inst Genet & Biophys Adriano Buzzati Traverso, I-80131 Naples, Italy
[2] Sigma Tau Pharmaceut Co, Ind Farmaceut Riunite, Res & Dev, I-00040 Pomezia, Rome, Italy
[3] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England
关键词
D O I
10.1074/jbc.M401418200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Placenta growth factor (PlGF) belongs to the vascular endothelial growth factor (VEGF) family and represents a key regulator of angiogenic events in pathological conditions. PlGF exerts its biological function through the binding and activation of the seven immunoglobulin-like domain receptor Flt-1, also known as VEGFR-1. Here, we report the first detailed mutagenesis studies that provide a basis for understanding molecular recognition between PlGF-1 and Flt-1, highlighting some of the residues that are critical for receptor recognition. Mutagenesis analysis, performed on the basis of a structural model of interaction between PlGF and the minimal binding domain of Flt-1, has led to the identification of several PlGF-1 residues involved in Flt-1 recognition. The two negatively charged residues, Asp-72 and Glu-73, located in the beta3-beta4 loop, are critical for Flt-1 binding. Other mutations, which bring about a significant decrease in PlGF binding activity, are Gln-27, located in the N-terminal alpha-helix, and Pro-98 and Tyr-100 on the beta6 strand. The mutation of one of the two glycosylated residues of PlGF, Asn-84, generates a PlGF variant with reduced binding activity. This indicates that, unlike in VEGF, glycosylation plays an important role in Flt-1 binding. The double mutation of residues Asp-72 and Glu-73 generates a PlGF variant unable to bind and activate the receptor molecules on the cell surface. This variant failed to induce in vitro capillary-like tube formation of primary endothelial cells or neo-angiogenesis in an in vivo chorioallantoic membrane assay.
引用
收藏
页码:43929 / 43939
页数:11
相关论文
共 36 条
[1]   Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 [J].
Autiero, M ;
Waltenberger, J ;
Communi, D ;
Kranz, A ;
Moons, L ;
Lambrechts, D ;
Kroll, J ;
Plaisance, S ;
De Mol, M ;
Bono, F ;
Kliche, S ;
Fellbrich, G ;
Ballmer-Hofer, K ;
Maglione, D ;
Mayr-Beyrle, U ;
Dewerchin, M ;
Dombrowski, S ;
Stanimirovic, D ;
Van Hummelen, P ;
Dehio, C ;
Hicklin, DJ ;
Persico, G ;
Herbert, JM ;
Communi, D ;
Shibuya, M ;
Collen, D ;
Conway, EM ;
Carmeliet, P .
NATURE MEDICINE, 2003, 9 (07) :936-943
[2]   In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor vascular endothelial growth factor [J].
Cao, YH ;
Linden, P ;
Shima, D ;
Browne, F ;
Folkman, J .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (11) :2507-2511
[3]   Placenta growth factor: Identification and characterization of a novel isoform generated by RNA alternative splicing [J].
Cao, YH ;
Ji, WDR ;
Qi, P ;
Rosin, A ;
Cao, YM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 235 (03) :493-498
[4]   Heterodimers of placenta growth factor vascular endothelial growth factor - Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR [J].
Cao, YH ;
Chen, H ;
Zhou, L ;
Chiang, MK ;
AnandApte, B ;
Weatherbee, JA ;
Wang, YD ;
Fang, FY ;
Flanagan, JG ;
Tsang, MLS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (06) :3154-3162
[5]   Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 [J].
Carmeliet, P ;
Ng, YS ;
Nuyens, D ;
Theilmeier, G ;
Brusselmans, K ;
Cornelissen, I ;
Ehler, E ;
Kakkar, VV ;
Stalmans, I ;
Mattot, V ;
Perriard, JC ;
Dewerchin, M ;
Flameng, W ;
Nagy, A ;
Lupu, F ;
Moons, L ;
Collen, D ;
D'Amore, PA ;
Shima, DT .
NATURE MEDICINE, 1999, 5 (05) :495-502
[6]   Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions [J].
Carmeliet, P ;
Moons, L ;
Luttun, A ;
Vincenti, V ;
Compernolle, V ;
De Mol, M ;
Wu, Y ;
Bon, F ;
Devy, L ;
Beck, H ;
Scholz, D ;
Acker, T ;
DiPalma, T ;
Dewerchin, M ;
Noel, A ;
Stalmans, I ;
Barra, A ;
Blacher, S ;
Vandendriessche, T ;
Ponten, A ;
Eriksson, U ;
Plate, KH ;
Foidart, JM ;
Schaper, W ;
Charnock-Jones, DS ;
Hicklin, DJ ;
Herbert, JM ;
Collen, D ;
Persico, MG .
NATURE MEDICINE, 2001, 7 (05) :575-583
[7]   The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1 [J].
Christinger, HW ;
Fuh, G ;
de Vos, AM ;
Wiesmann, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (11) :10382-10388
[8]   Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor placenta growth factor receptor Flt-1 required for binding and structural stability [J].
Davis-Smyth, T ;
Presta, LG ;
Ferrara, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (06) :3216-3222
[9]   Structure and function of placental growth factor [J].
De Falco, S ;
Gigante, B ;
Persico, MG .
TRENDS IN CARDIOVASCULAR MEDICINE, 2002, 12 (06) :241-246
[10]   Signal transduction and biological function of placenta growth factor in primary human trophoblast [J].
Desai, J ;
Holt-Shore, V ;
Torry, RJ ;
Caudle, MR ;
Torry, DS .
BIOLOGY OF REPRODUCTION, 1999, 60 (04) :887-892